IVERIC bio Inc (ISEE) Stock
ISEE is no longer traded. IVERIC bio was acquired by Astellas on July 11, 2023.
Each ISEE share was exchanged for $40.00 in cash. Prices on this page are historical; the last trade was July 10, 2023 at $39.95.
IVERIC bio stock price history
ISEE final trading statistics
- Final close
- $39.95
- Final trading day
- Jul 10, 2023
- Market cap at delisting
- $5.51B
- Shares outstanding
- 137.98M
- Final 52-week range
- $9.39 – $39.99
- Avg. volume (final 3 mo.)
- 5,052,675
- All-time high (split-adj.)
- $78.64 · Dec 2015
- All-time low (split-adj.)
- $0.93 · Oct 2019
- Return since IPO
- +51.9%
- Beta
- 1.10
- Book value / share
- $3.48
- Price / book
- 11.49
IVERIC bio annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2022 | $0.00 | -$175.7M | -$1.52 |
| FY2021 | $0.00 | -$114.2M | -$1.13 |
| FY2020 | $0.00 | -$84.5M | -$1.14 |
| FY2019 | $0.00 | -$58.9M | -$1.39 |
| FY2018 | $0.00 | $63.1M | -$1.67 |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About IVERIC bio Inc
IVERIC bio, Inc., a biopharmaceutical company, focuses on the discovery and development of novel treatments for retinal diseases with unmet medical needs. The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; GATHER2 that is in Phase 3 clinical trial for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD); and STAR or OPH2005 that is in Phase 2b clinical trial for the treatment of autosomal recessive Stargardt disease. Its preclinical product candidatures include IC-500, a high temperature requirement A serine peptidase 1 protein inhibitors for the treatment of GA and other age-related retinal diseases. The company also develops OPH2001 that has completed Phase 1/2a clinical trial of various doses of avacincaptad pegol (ACP) administered as a monotherapy for the treatment of GA; OPH2000, which has completed Phase 1/2a clinical trial of various doses of ACP administered in combination with Lucentis for the treatment of wet AMD; OPH2007 that has completed Phase 2a clinical trial for the treatment of wet AMD; and OPH2002, which has completed Phase 2a clinical trial for the treatment of idiopathic polypoidal choroidal vasculopathy. In addition, its minigene programs comprises miniCEP290 program for LCA10; miniABCA4 Program for STGD1; and miniUSH2A Program for usher syndrome type 2A-Related inherited retinal diseases (IRDs). The company was formerly known as Ophthotech Corporation and changed its name to IVERIC bio, Inc. in April 2019. The company was incorporated in 2007 and is based in Parsippany, New Jersey. As of July 11, 2023, IVERIC bio, Inc. operates as a subsidiary of Astellas US Holding, Inc.
IVERIC bio stock FAQ
What happened to IVERIC bio stock?
IVERIC bio was acquired by Astellas on July 11, 2023. Shareholders received $40.00 in cash for each share. ISEE stock stopped trading on the Nasdaq, with a final close of $39.95 on July 10, 2023.
What did IVERIC bio shareholders receive?
Each ISEE share was converted into $40.00 in cash. The deal was valued at about $5.9 billion.
Is ISEE stock still trading?
No. ISEE was delisted from the Nasdaq on July 11, 2023 and no longer trades on a U.S. exchange.
What was the last price of ISEE stock?
ISEE closed at $39.95 on its final trading day, July 10, 2023, for a market value of about $5.51B.
What were IVERIC bio's revenue and earnings in its last full fiscal year?
IVERIC bio reported revenue of $0.00 and net income of -$175.7M in fiscal 2022, its last full year as a public company.
When did IVERIC bio go public?
IVERIC bio Inc stock began trading on September 25, 2013.